Ignite Creation Date:
2025-12-25 @ 1:40 AM
Ignite Modification Date:
2025-12-31 @ 3:55 PM
Study NCT ID:
NCT00220194
Status:
COMPLETED
Last Update Posted:
2016-10-14
First Post:
2005-09-17
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Six-Month, Open-Label, Crossover Study Of the Maintenance Of Serum Testosterone And PSA Suppression After Switching Between Lupron 22.5 Mg And Eligard 22.5 Mg Or Zoladex 10.8 Mg And Eligard 22.5 Mg In Patients With Advanced Prostate Cancer
Sponsor:
San Bernardino Urological Associates Medical Group Inc
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
SBU001
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None